Imagion Biosystems Limited announced it has appointed Isaac Bright, MD as CEO, effective 20 June 2023. Dr. Bright is a results-focused business leader and brings to Imagion over 20 years of experience as a health industry executive and venture capitalist in medical technology, biopharmaceuticals, and oncology-based molecular diagnostics. Dr. Bright most recently served as Co-Founder, CEO, and Chairman of RubrYc Therapeutics Inc. before its trade sale to iBio Inc. in September 2022.

Prior to launching RubrYc, Dr. Bright was Chief Business Officer for molecular diagnostics innovator HealthTell Inc., driving its trade sale to iCarbonX, concomitant with RubrYc's launch in 2018. Prior to that, Dr. Bright served as VP, Corporate Development for Synthetic Biologics Inc. and consulting Chief Business Officer for synthetic biology innovator musebio Inc. (currently Incripta Inc.) as it secured its $23 million Series B Preferred financing. Dr. Bright was the first American Partner investing with Merieux Developpement (currently, Merieux Equity Partners) from 2012 through 2016, during which he helped the firm raise €150 million Merieux Participations 2 fund.

With Merieux, Dr. Bright led investments and Board representation for Imaginab Inc., Kalila Medical Inc. until its acquisition by Abbott, and Twist Bioscience before its IPO. Dr. Bright's startup experience began as he built and led QuantaLife Inc.'s Corporate Development and Molecular Diagnostics functions from 2009-2011, leading to QuantaLife's acquisition by Bio-Rad Laboratories Inc. Previously, Dr. Bright served as Sr. Associate, Corporate Development and Director, Business Development - Neuromodulation for global medtech leader Medtronic. Dr. Bright earned his bachelor's degree in biochemistry from Pepperdine University, his medical degree from the Stanford University School of Medicine and was a Howard E. Mitchell Fellow earning his MBA from the Wharton School at the University of Pennsylvania.

The hiring of Dr. Bright follows from the recent announcement on 28 April 2023 regarding the plan for Bob Proulx to retire from the role of CEO, remaining as Chairman of the Board.